ARS Wealth Advisors Group 13F: Exits Stryker (SYK) Stake

ARS Wealth Advisors Group has sold all its shares of Stryker Corporation (NYSE:SYK) as of the latest filing on October 16, 2026. This move involved 775 shares, leaving the firm with a stake valued around $228,000 at the recent trading price of $294.09.

What Changed in ARS Wealth Advisors Group's Stryker Position

ARS Wealth Advisors cut its position in Stryker, selling all 775 shares, which represents a 100% decrease in its holdings. This marks the firm's complete exit from its investment in the medical technology company.

Other Institutional Activity in Stryker

Several other notable institutional players were also active with Stryker shares. Blackrock Inc. reduced its holdings by 187,697 shares, leaving it with 27,414,742 shares valued at about $8.08 billion. Meanwhile, Vanguard Capital Management LLC added 154,439 shares, bringing its total to 22,536,843 shares worth around $6.64 billion. JPMorgan Chase grew its stake by 1,664,175 shares, totaling 17,260,943 shares valued at about $5.09 billion. In contrast, Greenleaf Trust decreased its position by 709,231 shares, holding 15,228,545 shares worth about $4.49 billion.

Stryker Corporation Stock Up 4.4%

As of October 16, 2026, Stryker shares are trading around $294.09, which is below both its 50-day moving average of $300.80 and its 200-day average of $326.94. The stock is also 25.1% lower than its 52-week high of $392.55, although it sits 10.1% above its 52-week low of $267.00. The mean price target among analysts is $362.62, suggesting that the stock is currently undervalued compared to expectations.

Recent Earnings

Stryker reported revenue of about $25.83 billion over the trailing twelve months with an earnings per share (EPS) of $9.65. The company has a net margin of 14.4% and a return on equity (ROE) of 16.5%. The next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Stryker Corporation

Several insiders sold shares earlier this year, including Robert S. Debra King sold 826 shares at an average price of $336.30 on August 18, 2026. Ronda E. Stryker, a director, sold a significant 350,000 shares on August 19, 2026, though details on the price were not reported.

Analysts Set New Price Targets

On September 22, 2026, TD Cowen maintained a Hold rating with a target of $298, down from $355. Stifel also maintained a Buy rating with a revised target of $330, down from $360 on September 30. Truist Securities kept its Hold rating while lowering the target to $310 from $340 on October 7. Barclays initiated coverage with an Overweight rating and a target of $375 on the same day. BTIG maintained a Buy rating but reduced its target from $358 to $316 by October 12.

About Stryker Corporation

Stryker Corporation is a leading medical technology firm that specializes in medical devices. It operates in two main segments: MedSurg and Neurotechnology, and Orthopaedics. This recent sell-off by ARS Wealth Advisors reflects a significant decision in the context of ongoing changes among other institutional investors.

Bottom Line

Looking forward, investors will watch for Stryker's upcoming earnings report on October 29, 2026, to gauge its financial health. The recent activity from ARS Wealth Advisors and other large funds hints at a shifting landscape in Stryker's investment community, as seen in the latest filings. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.